Literature DB >> 35817941

Lipocalin-2-Mediated Insufficient Oligodendrocyte Progenitor Cell Remyelination for White Matter Injury After Subarachnoid Hemorrhage via SCL22A17 Receptor/Early Growth Response Protein 1 Signaling.

Qiang Li1,2,3,4, Xufang Ru1,3,4, Yang Yang1,3,4, Hengli Zhao1,3,4, Jie Qu1,3,4, Weixiang Chen1,3,4, Pengyu Pan1,3,4, Huaizhen Ruan2, Chaojun Li5, Yujie Chen6,7,8, Hua Feng1,3,4.   

Abstract

Insufficient remyelination due to impaired oligodendrocyte precursor cell (OPC) differentiation and maturation is strongly associated with irreversible white matter injury (WMI) and neurological deficits. We analyzed whole transcriptome expression to elucidate the potential role and underlying mechanism of action of lipocalin-2 (LCN2) in OPC differentiation and WMI and identified the receptor SCL22A17 and downstream transcription factor early growth response protein 1 (EGR1) as the key signals contributing to LCN2-mediated insufficient OPC remyelination. In LCN-knockdown and OPC EGR1 conditional-knockout mice, we discovered enhanced OPC differentiation in developing and injured white matter (WM); consistent with this, the specific inactivation of LCN2/SCl22A17/EGR1 signaling promoted remyelination and neurological recovery in both atypical, acute WMI due to subarachnoid hemorrhage and typical, chronic WMI due to multiple sclerosis. This potentially represents a novel strategy to enhance differentiation and remyelination in patients with white matter injury.
© 2022. The Author(s).

Entities:  

Keywords:  Early growth response protein 1; Lipocalin-2; Multiple sclerosis; Oligodendrocyte progenitor cell; Remyelination; Subarachnoid hemorrhage; White matter injury

Year:  2022        PMID: 35817941     DOI: 10.1007/s12264-022-00906-w

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.271


  61 in total

Review 1.  Spontaneous subarachnoid haemorrhage.

Authors:  R Loch Macdonald; Tom A Schweizer
Journal:  Lancet       Date:  2016-09-13       Impact factor: 79.321

Review 2.  The complex world of oligodendroglial differentiation inhibitors.

Authors:  David Kremer; Orhan Aktas; Hans-Peter Hartung; Patrick Küry
Journal:  Ann Neurol       Date:  2011-04       Impact factor: 10.422

3.  Remyelination: a good neuroprotective strategy for preventing axonal degeneration?

Authors:  Pablo Villoslada; Elena H Martinez-Lapiscina
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

Review 4.  Lipocalin-2 as a therapeutic target for brain injury: An astrocentric perspective.

Authors:  Kyoungho Suk
Journal:  Prog Neurobiol       Date:  2016-08-04       Impact factor: 11.685

5.  Long-Term Cognitive Outcome following Aneurysmal Subarachnoid Haemorrhage.

Authors:  Ben Gaastra; Frederick Ewbank; William Tapper; Diederik Bulters; Ian Galea
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-11-10       Impact factor: 2.136

6.  A timeline of oligodendrocyte death and proliferation following experimental subarachnoid hemorrhage.

Authors:  Kang Peng; Sravanthi Koduri; Fenghui Ye; Jinting Yang; Richard F Keep; Guohua Xi; Ya Hua
Journal:  CNS Neurosci Ther       Date:  2022-02-11       Impact factor: 7.035

7.  Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Authors:  Faiez Al Nimer; Christina Elliott; Joakim Bergman; Mohsen Khademi; Ann M Dring; Shahin Aeinehband; Tommy Bergenheim; Jeppe Romme Christensen; Finn Sellebjerg; Anders Svenningsson; Christopher Linington; Tomas Olsson; Fredrik Piehl
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-07

Review 8.  Origin and dynamics of oligodendrocytes in the developing brain: Implications for perinatal white matter injury.

Authors:  Erik van Tilborg; Caroline G M de Theije; Maurik van Hal; Nienke Wagenaar; Linda S de Vries; Manon J Benders; David H Rowitch; Cora H Nijboer
Journal:  Glia       Date:  2017-11-14       Impact factor: 7.452

Review 9.  Secondary White Matter Injury and Therapeutic Targets After Subarachnoid Hemorrhage.

Authors:  Xufang Ru; Ling Gao; Jiru Zhou; Qiang Li; Shilun Zuo; Yujie Chen; Zhi Liu; Hua Feng
Journal:  Front Neurol       Date:  2021-07-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.